Deflazacort Designated Fast Track Status for Duchenne Muscular Dystrophy
Marathon Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Fast Track designation to deflazacort for the treatment of patients with Duchenne Muscular Dystrophy (DMD). Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties.
Currently numerous clinical and preclinical studies of deflazacort are underway to support approval in patients with DMD. Maraton plans on submitting a New Drug Application (NDA) in early 2016. The FDA previously granted Orphan Drug designation to deflazacort for the treatment of DMD.
For more information visit Marathonpharma.com.